We are experiencing a renaissance in BioPharma. Robust specialty drug pipelines are promising paradigm-shifting innovation in notoriously challenging therapeutic areas like Oncology, Neurology, and Rare Disease. While promising, this progress comes at a cost – the influx of high price drug launches targeting a broader population is expected to threaten budget sustainability and lead to more aggressive payer action to erode price and restrict access.
To sustain portfolio value, drug manufacturers must be part of defining the solution, and “value-based” pricing is often identified as the ideal path forward. While this approach is promising, there are substantial challenges and considerations.
On this Webcast, KPMG’s Pete Gilmore and Amy Hunckler will: